CEO Greetings

"We supply the highest quality pharmaceuticals
so that people can enjoy a better life."

I would like to express my deepest gratitude to everyone who cares for and loves Hana Pharm.

Based on continuous challenge and innovation, Hana Pharm has achieved sustainable growth and is taking powerful steps to leap forward as a global pharmaceutical company beyond Korea.

A powerful step towards the world

Hana Pharm is further strengthening its production competitiveness through the completion of the Hagil CMO plant and the construction of the new Pyeongtaek plant. We are growing into a trusted partner in the global pharmaceutical market by accelerating our export efforts.
The Hagil CMO plant successfully passed the EU-GMP inspection and obtained GMP certification from the EMA, which stands as one of the most significant achievements in the domestic pharmaceutical industry. Furthermore, by securing Japan's PMDA certification in June 2025, the Hagil CMO plant has established itself as a globally recognized production hub. These international certifications signify that Hana Pharm has built a solid foundation to supply high-quality pharmaceuticals to countries all over the world.

Endless growth

Our export performance in international markets is further elevating Hana Pharm’s global brand value.
- Export to Japan: The first shipment of our new anesthetic drug, ‘Anerem,’ was successfully completed, serving as a prime example of Hana Pharm meeting global quality standards.
- Export to Europe: We achieved our first export milestone as our new anesthetic drug is now being supplied across Europe through Germany’s PAION AG, and we plan to expand our export reach to North America in the future.

- Southeast Asia and Other Regions: We are diversifying our export foundation by signing contract manufacturing agreements with various Southeast Asian countries, including the Philippines, Singapore, and Indonesia.
In this way, Hana Pharm is dedicated to expanding its export regions and strengthening partnerships to achieve sustainable growth in the global market.

Endless challenge

Hana Pharm is not resting on its laurels but is preparing for the future by developing innovative new drugs and strengthening research capabilities. We are on the verge of entering Phase 1 clinical trials for our P-CAB (Potassium-Competitive Acid Blocker) treatment for gastroesophageal reflux disease. Furthermore, we continue to achieve significant R&D milestones, such as the 2024 launch of ‘Paramet Duo Tab,’ an incrementally modified drug for gastric ulcers. Moving forward, we will secure global innovative medicines and core technologies through active R&D investment to create new growth engines.

Based on strong corporate ethics and transparent management, Hana Pharm practices "Jeong-do" (Right-way) management, where all employees fulfill their ethical responsibilities. We will continue to place the trust of our customers as our highest priority and do our utmost to emerge as a global pharmaceutical company that contributes to the promotion of human health.

Thank you.

Tae-Hong Choi CEO, Hana Pharm Co., Ltd